Hospital
ST Lukes Hospital
ST Lukes Hospital was paid $20.74M by Medicaid between Jan 2018 and Dec 2024, across 326 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoST LUKES HOSPITAL
BETHLEHEM, PA 18015
BETHLEHEM, PA 18015
33aNPI1013933175assigned 07/14/2006
33bProvider typeChildren's Hospital
28Total paid$20.74M
24GClaims427,032
24DCodes billed326
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WOLFE, SCOTT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,581 | $187K | |
| 2019 | 5,097 | $389K | |
| 2020 | 56,379 | $2.92M | |
| 2021 | 184,078 | $7.64M | |
| 2022 | 58,962 | $3.65M | |
| 2023 | 67,776 | $3.40M | |
| 2024incomplete | 53,159 | $2.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 26,573 | 25,576 | $3.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 16,093 | 15,363 | $2.48M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 11% | 63,539 | 16,510 | $2.34M |
| G0378 | Hospital observation service, per hour | 11% | 2,422 | 2,190 | $2.32M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.6% | 14,470 | 13,669 | $1.16M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.2% | 11,369 | 11,024 | $879K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 4,959 | 4,675 | $821K |
| X0621 | 3.7% | 3,466 | 2,384 | $777K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.4% | 4,643 | 4,418 | $492K |
| 99050 | 2.0% | 4,155 | 3,955 | $412K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.5% | 13,384 | 12,964 | $315K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.5% | 13,159 | 12,743 | $308K |
314 more codes
| 99203 | Doctor's office visit, new patient (routine) | 1.3% | 2,509 | $277K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.3% | 6,074 | $273K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,496 | $196K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,431 | $190K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,898 | $170K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,684 | $169K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,596 | $141K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 887 | $136K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 519 | $122K |
| 80053 | Comprehensive metabolic panel | <1% | 12,541 | $122K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 139 | $111K |
| 80050 | General health panel | <1% | 2,426 | $105K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,005 | $102K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,775 | $101K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 369 | $95K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,601 | $78K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,394 | $74K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 334 | $74K |
| 97162 | <1% | 946 | $63K | |
| X0616 | <1% | 337 | $59K | |
| 80061 | Lipid panel | <1% | 4,297 | $57K |
| 87070 | <1% | 6,457 | $56K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 618 | $53K |
| 97161 | <1% | 770 | $51K | |
| X0620 | <1% | 283 | $51K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 703 | $51K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,478 | $46K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 438 | $46K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 165 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,110 | $42K |
| 77066 | Tomosynthesis, mammo | <1% | 483 | $40K |
| 76642 | <1% | 1,010 | $40K | |
| 76813 | <1% | 720 | $38K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 442 | $38K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 732 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,853 | $37K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,638 | $34K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 224 | $32K |
| 87631 | <1% | 238 | $32K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 577 | $30K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 465 | $29K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,023 | $28K |
| 87150 | <1% | 656 | $27K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 699 | $25K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,849 | $25K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 769 | $25K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,130 | $22K |
| 300 | Patient transfer system <300 | <1% | 456 | $22K |
| 95811 | <1% | 42 | $21K | |
| 87480 | <1% | 894 | $21K | |
| 87660 | <1% | 897 | $21K | |
| 92567 | <1% | 1,642 | $20K | |
| 80081 | <1% | 243 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 460 | $19K |
| 86803 | <1% | 1,003 | $19K | |
| 77065 | Tomosynthesis, mammo | <1% | 280 | $18K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 84 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,540 | $17K |
| 87536 | <1% | 158 | $17K | |
| 88341 | <1% | 264 | $16K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,383 | $16K |
| 76801 | <1% | 389 | $15K | |
| 95886 | <1% | 334 | $15K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,165 | $15K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 84 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,308 | $14K |
| 86480 | <1% | 203 | $13K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 187 | $13K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 745 | $13K |
| 81001 | <1% | 4,917 | $13K | |
| 72082 | <1% | 325 | $13K | |
| 88342 | <1% | 418 | $13K | |
| 86003 | <1% | 102 | $13K | |
| 88344 | <1% | 161 | $13K | |
| 82728 | <1% | 1,089 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 412 | $12K |
| 71250 | <1% | 223 | $12K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 359 | $12K |
| 73610 | <1% | 648 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 231 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,163 | $11K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 82 | $11K |
| 83970 | <1% | 284 | $11K | |
| 82570 | <1% | 1,604 | $11K | |
| S9083 | Global fee urgent care centers | <1% | 105 | $11K |
| 87510 | <1% | 724 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 173 | $11K |
| 87186 | <1% | 1,262 | $10K | |
| 93017 | <1% | 288 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 442 | $10K |
| 84439 | <1% | 1,300 | $10K | |
| 92587 | <1% | 325 | $9K | |
| 73110 | <1% | 653 | $9K | |
| 97163 | <1% | 180 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 232 | $9K |
| 87077 | <1% | 1,218 | $9K | |
| 84702 | <1% | 558 | $8K | |
| 19083 | <1% | 78 | $8K | |
| 82607 | <1% | 785 | $8K | |
| 85027 | <1% | 1,386 | $8K | |
| 83540 | <1% | 951 | $8K | |
| 82043 | <1% | 1,009 | $8K | |
| 93971 | <1% | 149 | $8K | |
| 76770 | <1% | 198 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,599 | $7K |
| 76536 | <1% | 154 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 625 | $7K |
| 84484 | <1% | 1,105 | $7K | |
| 70496 | <1% | 43 | $7K | |
| 83690 | <1% | 1,508 | $6K | |
| 70498 | <1% | 38 | $6K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 312 | $6K |
| 92557 | <1% | 255 | $6K | |
| J3490 | Unclassified drugs | <1% | 1,907 | $6K |
| 82784 | <1% | 372 | $6K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 421 | $6K |
| 87340 | <1% | 427 | $6K | |
| 97164 | <1% | 199 | $6K | |
| 87653 | <1% | 147 | $6K | |
| 73030 | <1% | 544 | $6K | |
| 73562 | <1% | 401 | $6K | |
| 73630 | <1% | 607 | $5K | |
| 83735 | <1% | 861 | $5K | |
| 86038 | <1% | 335 | $5K | |
| 86255 | <1% | 310 | $5K | |
| 94726 | <1% | 223 | $5K | |
| 94729 | <1% | 203 | $5K | |
| 84153 | <1% | 236 | $5K | |
| 73560 | <1% | 382 | $5K | |
| 97167 | <1% | 73 | $5K | |
| 72141 | <1% | 24 | $5K | |
| 72110 | <1% | 256 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 30 | $5K |
| 84403 | <1% | 180 | $4K | |
| 73130 | <1% | 473 | $4K | |
| 73502 | <1% | 290 | $4K | |
| 73564 | <1% | 311 | $4K | |
| 96415 | <1% | 189 | $4K | |
| 88313 | <1% | 85 | $4K | |
| 90715 | <1% | 318 | $4K | |
| 83550 | <1% | 850 | $4K | |
| 93226 | <1% | 116 | $4K | |
| 86618 | <1% | 171 | $4K | |
| 84146 | <1% | 165 | $4K | |
| 86850 | <1% | 558 | $4K | |
| 72100 | <1% | 225 | $4K | |
| 76818 | <1% | 54 | $4K | |
| 81003 | <1% | 1,254 | $4K | |
| 73590 | <1% | 236 | $3K | |
| 96367 | <1% | 215 | $3K | |
| 85610 | <1% | 1,155 | $3K | |
| 95708 | <1% | 43 | $3K | |
| 86235 | <1% | 106 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 327 | $3K |
| 73221 | <1% | 12 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 107 | $3K |
| 86361 | <1% | 102 | $3K | |
| 86592 | <1% | 745 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 54 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 57 | $3K |
| 84703 | <1% | 288 | $3K | |
| 83655 | <1% | 255 | $3K | |
| 82950 | <1% | 404 | $3K | |
| 83880 | <1% | 124 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $3K |
| 82746 | <1% | 255 | $3K | |
| 85379 | <1% | 291 | $2K | |
| 80076 | <1% | 307 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 86 | $2K |
| 87147 | <1% | 513 | $2K | |
| 87205 | <1% | 520 | $2K | |
| 76820 | <1% | 98 | $2K | |
| 86140 | <1% | 802 | $2K | |
| 97166 | <1% | 43 | $2K | |
| 92556 | <1% | 131 | $2K | |
| OP250 | <1% | 1,259 | $2K | |
| 93225 | <1% | 130 | $2K | |
| 74018 | <1% | 163 | $2K | |
| 84100 | <1% | 383 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,132 | $2K |
| 87522 | Neg quan hep c or qual rna | <1% | 48 | $2K |
| 93970 | <1% | 27 | $2K | |
| 85652 | <1% | 688 | $2K | |
| 86900 | <1% | 592 | $2K | |
| 88142 | <1% | 117 | $2K | |
| 86901 | <1% | 581 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 115 | $2K |
| 97597 | <1% | 155 | $2K | |
| 76882 | <1% | 221 | $2K | |
| 95911 | <1% | 29 | $2K | |
| 86706 | <1% | 138 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 41 | $2K |
| 84156 | <1% | 449 | $2K | |
| 83001 | <1% | 98 | $2K | |
| 73080 | <1% | 156 | $2K | |
| 82105 | <1% | 87 | $2K | |
| 86800 | <1% | 95 | $2K | |
| 86430 | <1% | 227 | $2K | |
| 86704 | <1% | 104 | $1K | |
| 84402 | <1% | 54 | $1K | |
| 87255 | <1% | 35 | $1K | |
| 92593 | <1% | 106 | $1K | |
| 85730 | <1% | 287 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 763 | $1K |
| 73140 | <1% | 159 | $1K | |
| 93923 | <1% | 39 | $1K | |
| 94060 | <1% | 134 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,839 | $1K |
| 73552 | <1% | 72 | $1K | |
| 83002 | <1% | 62 | $1K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 13 | $992.20 |
| 82550 | <1% | 181 | $978.86 | |
| X0592 | <1% | 55 | $965.70 | |
| 70486 | <1% | 12 | $917.76 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 172 | $906.47 |
| 92555 | <1% | 121 | $901.29 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 101 | $897.96 |
| 95819 | <1% | 70 | $868.42 | |
| 82948 | <1% | 746 | $865.97 | |
| 85007 | <1% | 275 | $860.96 | |
| 81002 | <1% | 252 | $823.54 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 13 | $790.76 |
| 86705 | <1% | 56 | $776.84 | |
| 87081 | <1% | 139 | $746.24 | |
| 84550 | <1% | 139 | $742.21 | |
| 87430 | <1% | 85 | $711.55 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $707.20 |
| 72170 | <1% | 81 | $691.10 | |
| 84481 | <1% | 28 | $657.50 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,356 | $642.98 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $620.46 |
| 72040 | <1% | 45 | $617.35 | |
| 86200 | <1% | 43 | $567.97 | |
| 87040 | <1% | 46 | $557.20 | |
| 84480 | <1% | 72 | $556.23 | |
| 86376 | <1% | 73 | $548.06 | |
| 82785 | <1% | 32 | $526.12 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 155 | $511.00 |
| 82248 | <1% | 81 | $508.78 | |
| 99152 | <1% | 99 | $501.03 | |
| 83605 | <1% | 92 | $475.20 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 13 | $474.48 |
| 81025 | <1% | 370 | $460.56 | |
| 80164 | <1% | 25 | $436.15 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 918 | $424.43 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,071 | $403.87 |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 18 | $371.81 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,199 | $359.43 |
| 88304 | <1% | 64 | $356.63 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,139 | $352.99 |
| 73090 | <1% | 29 | $337.33 | |
| 95816 | <1% | 29 | $330.26 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 43 | $323.80 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16 | $301.83 |
| 72050 | <1% | 14 | $287.87 | |
| 87209 | <1% | 13 | $276.85 | |
| 82247 | <1% | 37 | $259.21 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 32 | $253.44 |
| 82947 | <1% | 82 | $251.77 | |
| 92552 | <1% | 29 | $239.99 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,552 | $236.29 |
| 84132 | <1% | 54 | $212.67 | |
| 86787 | <1% | 13 | $206.59 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,889 | $186.57 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 491 | $167.57 |
| 84425 | <1% | 26 | $157.11 | |
| 83615 | <1% | 29 | $148.37 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 641 | $142.26 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,323 | $141.86 |
| 84590 | <1% | 12 | $137.80 | |
| 82803 | <1% | 13 | $137.52 | |
| 86769 | <1% | 12 | $136.96 | |
| 94010 | <1% | 14 | $128.42 | |
| 87102 | <1% | 12 | $128.04 | |
| 85014 | <1% | 58 | $121.85 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 157 | $118.16 |
| 83020 | <1% | 12 | $116.60 | |
| 82977 | <1% | 12 | $116.05 | |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $109.60 |
| 87177 | <1% | 13 | $103.35 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 56 | $94.72 |
| 80178 | <1% | 14 | $87.25 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,928 | $78.65 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 111 | $71.84 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 707 | $70.88 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,840 | $58.40 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 43 | $45.85 |
| 76937 | <1% | 12 | $43.79 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 225 | $42.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 410 | $42.07 |
| 84295 | <1% | 14 | $39.93 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 39 | $38.35 |
| 82077 | <1% | 12 | $21.06 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 33 | $21.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 138 | $14.32 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 32 | $10.62 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 14 | $8.90 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 481 | $0.08 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 922 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 27 | $0.00 |
| 81513 | 0% | 40 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 18 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 64 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 154 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 14 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 241 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 73 | $0.00 |
| A9270 | Non-covered item or service | 0% | 436 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 139 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 67 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 13 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 13 | $0.00 |
| C1769 | Guide wire | 0% | 12 | $0.00 |
| 94760 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLFE, SCOTT (SENIOR VP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.